Effects of proton pump inhibitors on pediatric inflammatory esophagogastric polyps

Digestion. 2012;85(3):179-84. doi: 10.1159/000327909. Epub 2012 Jan 13.

Abstract

Background: The aim of this study was to investigate the effects of proton pump inhibitors on symptomatic inflammatory esophagogastric polyps (IEPs) in a pediatric cohort and to determine the optimal duration of treatment.

Methods: The 11 patients with IEPs were managed with lansoprazole. Follow-up endoscopies were performed at 2 and 6 months after the start of medication. Medication was discontinued when the clinical symptoms completely resolved and the polyp size was reduced by more than 50% compared to the initial size.

Results: The initial polyp size was 13.7 ± 3.3 mm. After 2 months of medication, the polyp size was reduced to 8.0 ± 5.8 mm. At 6 months, the polyp size was 4.7 ± 2.2 mm. The mean duration of medication was 4.8 ± 2.1 months. The duration of medication and the change in the polyp size appeared to have a linear correlation (p < 0.001). According to the formula used to calculate polyp size, the optimal duration of treatment was more than 7 months for complete resolution of the polyps.

Conclusions: Proton pump inhibitor was effective for the treatment of IEPs. About 5 months of lansoprazole was adequate to treat IEPs in children. The optimal duration for complete resolution of the polyp might be more than 7 months.

Publication types

  • Case Reports

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage*
  • 2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects
  • Adolescent
  • Child
  • Child, Preschool
  • Cohort Studies
  • Endoscopy
  • Esophageal Diseases / complications
  • Esophageal Diseases / drug therapy*
  • Esophageal Diseases / pathology
  • Esophagogastric Junction / pathology*
  • Female
  • Follow-Up Studies
  • Humans
  • Lansoprazole
  • Male
  • Polyps / complications
  • Polyps / drug therapy*
  • Polyps / pathology
  • Prospective Studies
  • Proton Pump Inhibitors / administration & dosage*
  • Proton Pump Inhibitors / adverse effects
  • Stomach Diseases / complications
  • Stomach Diseases / drug therapy*
  • Stomach Diseases / pathology
  • Time Factors

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Proton Pump Inhibitors
  • Lansoprazole